Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
FDA supplemental approval of a buprenorphine–naloxone combination tablet under a Risk Evaluation and Mitigation Strategy (REMS); this is a regulatory action, not a clinical trial, and does not report efficacy or safety trial outcomes.
FDA supplemental approval for a REMS (Risk Evaluation and Mitigation Strategy) on an established generic drug; a regulatory action, not a clinical trial.
FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for mycophenolate mofetil; this is a regulatory action, not a clinical efficacy or safety trial.
FDA approval of a generic sugammadex sodium formulation; regulatory action confirms manufacturing and bioequivalence standards but does not report clinical trial efficacy data.
FDA supplemental approval for labeling changes to an established lithium carbonate product; no clinical trial data or efficacy comparisons are provided in this regulatory record.
FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for an existing combination analgesic; this is a regulatory action, not a clinical efficacy study.